The document this correction applies to
Timely disclosureWhat was corrected and how
A subsequent correction by the company to the contents of an already published filing.
Financial Results Summary for the Third Quarter of the Fiscal Year Ending September 2026〔Japanese GAAP〕(Consolidated)
Open the original document<Attached materials, pages 10 and 11> [3] Notes to Quarterly Consolidated Financial Statements (Segment Information) Information on revenue and profit or loss by reportable segment and disaggregated revenue information: cumulative third-quarter period (from 1 October 2025 to 30 June 2026)
Item Revenue: Blood processing / Medical Support Business 430,408 / Total 430,408 / Total 430,408 / Amount recognized in the quarterly consolidated statement of income 430,408, Item Revenue: Raw material sales / Medical Support Business 417,395 / Total 417,395 / Total 417,395 / Amount recognized in the quarterly consolidated statement of income 417,395
Item Revenue: Blood processing / Medical Support Business 365,164 / Total 365,164 / Total 365,184 / Amount recognized in the quarterly consolidated statement of income 365,184, Item Revenue: Raw material sales / Medical Support Business 482,640 / Total 482,640 / Total 482,640 / Amount recognized in the quarterly consolidated statement of income 482,640
The correction has no impact on consolidated operating results or consolidated financial position.
Because errors were discovered in the figures for the cumulative third-quarter period in the segment information after the publication of the Financial Results Summary for the Third Quarter of the Fiscal Year Ending September 2026〔Japanese GAAP〕(Consolidated), the figures are being corrected.
| Item | Details |
|---|---|
| Disclosure subject to correction | Financial Results Summary for the Third Quarter of the Fiscal Year Ending September 2026〔Japanese GAAP〕(Consolidated) |
| Original disclosure date | 7 August 2026 |
| Location of correction | <Attached materials, pages 10 and 11> [3] Notes to Quarterly Consolidated Financial Statements (Segment Information) Information on revenue and profit or loss by reportable segment and disaggregated revenue information: cumulative third-quarter period (from 1 October 2025 to 30 June 2026) |
| Details of correction | Item Revenue: Blood processing / Medical Support Business 430,408 / Total 430,408 / Total 430,408 / Amount recognized in the quarterly consolidated statement of income 430,408, Item Revenue: Raw material sales / Medical Support Business 417,395 / Total 417,395 / Total 417,395 / Amount recognized in the quarterly consolidated statement of income 417,395 → Item Revenue: Blood processing / Medical Support Business 365,164 / Total 365,164 / Total 365,184 / Amount recognized in the quarterly consolidated statement of income 365,184, Item Revenue: Raw material sales / Medical Support Business 482,640 / Total 482,640 / Total 482,640 / Amount recognized in the quarterly consolidated statement of income 482,640 |
| Reason for correction | Because errors were discovered in the figures for the cumulative third-quarter period in the segment information after the publication of the Financial Results Summary for the Third Quarter of the Fiscal Year Ending September 2026〔Japanese GAAP〕(Consolidated), the figures are being corrected. |
| Impact on Business Performance | The correction has no impact on consolidated operating results or consolidated financial position. |
The reasons the company gives
The company's own explanation, not something inferred from the numbers.After the original financial results summary was published, it was discovered that there were errors in the figures for the cumulative third-quarter period in the segment information.